Safety and Efficacy of Lacosamide as Additional Therapy in Patients Suffering From Epileptic Tonic-Clonic Seizures
Completed · Phase 3 · NCT02408549
Conditions: Epilepsy
At a glance
- Research payments reported, 2025
- $11,255
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 239
About the trial
- Sponsor
- UCB BIOSCIENCES, Inc.
- Tested
- Lacosamide Tablet (drug), Lacosamide Oral Solution (drug)
- Dates
- Started 2015-08-03; completion 2023-03-30
- Results posted
- Yes
Assessment of long-term safety and efficacy of oral lacosamide (LCM) as an adjunctive therapy for uncontrolled primary generalized tonic-clonic seizures (PGTCS) in subjects \>= 4 years of age with idiopathic generalized epilepsy (IGE). This study will enroll subjects from the LCM SP0982 \[NCT02408523\] study.
From ClinicalTrials.gov, last updated 2023-12-14. Full record, eligibility and contacts (opens in a new tab)
Industry funding
UCB Biosciences Inc. reported $11,255 in research payments for this study in 2025 (3 payments).
Products named: Vimpat
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- $7,108
- New York University $2,345
- Ranier Clinical Research $1,802
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.